Biotech
Biotechnology companies, trials, and applied biological innovation.
BioVie completes Phase 2 SUNRISE-PD trial in early-stage Parkinson's disease
BioVie said it has completed the last patient evaluation visit in its Phase 2 SUNRISE-PD trial of bezisterim in early-stage Parkinson’s disease. Topline data are targeted for Q3 2026.
Anthill launches US availability of Anthill Cloud for life sciences
Anthill said Anthill Cloud is now available in the US for pharmaceutical, biotech and medtech commercial and medical teams. The company describes the platform as an AI-powered content-excellence system for life sciences.
Dogwood Therapeutics starts Halneuron Phase 2b extension study
Dogwood Therapeutics said it has started a 12-week open-label extension study of Halneuron after a positive interim assessment in its ongoing Phase 2b chemotherapy-induced neuropathic pain trial. The company said the follow-on study will add safety and efficacy data for its planned FDA submission package and future Phase 3 program.
Lakewood-Amedex reports positive data for lead diabetic-foot-ulcer candidate
Lakewood-Amedex said its lead candidate Nu-3 produced positive development and manufacturing data supporting advancement toward a planned Phase 2 trial in mildly infected diabetic foot ulcers.
Daré Bioscience initiates Phase 2 study of DARE-HPV
Daré Bioscience said it has started a Phase 2 clinical study of DARE-HPV, its investigational vaginal insert containing lopinavir and ritonavir for persistent high-risk HPV infection. The program follows earlier FDA clearance of the IND and is supported by ARPA-H funding.
Quince Therapeutics says it acquired Orphai and lined up up to $187 million in financing
Quince Therapeutics said it completed its acquisition of Orphai Therapeutics and arranged a concurrent private placement that could raise up to $187 million in gross proceeds, adding Orphai’s pulmonary program to its pipeline.
Avalo Therapeutics reports positive Phase 2 LOTUS data in hidradenitis suppurativa
Avalo Therapeutics said its Phase 2 LOTUS trial of abdakibart met the primary endpoint in hidradenitis suppurativa.
NIH-funded breakthrough shrinks CRISPR for precision delivery in the body
Researchers say a compact CRISPR system and an engineered variant could make gene editing easier to deliver inside the body.
Avacta announces 2026 Science Day event
Avacta has announced a May 6 Science Day in London focused on its pre|CISION platform and recent scientific progress.